Calypte Only Company with Full Menu of Tests.
| eröffnet am: | 08.04.05 22:44 von: | Brokersince1994 |
| neuester Beitrag: | 03.03.11 19:06 von: | schubby1 |
| Anzahl Beiträge: | 3593 | |
| Leser gesamt: | 349794 | |
| davon Heute: | 329 | |
bewertet mit 8 Sternen |
||
|
|
||
19.05.05 12:02
#401
Brokersince1994
Rede hier nicht im Namen anderer,
wer sich zum Clown macht das wissen alle hier die reinschauen....
wer sich zum Clown macht das wissen alle hier die reinschauen....
19.05.05 12:11
#402
Brokersince1994
Nochmal für dich Ausführlich Joelu
Stand der Dinge:
Das ist auch aus dem Filing (Aktuell)
PROSPECTUS SUMMARY THE FOLLOWING SUMMARY HIGHLIGHTS SELECTED INFORMATION CONTAINED ELSEWHERE IN THIS PROSPECTUS OR INCORPORATED BY REFERENCE IN THIS PROSPECTUS. THIS SUMMARY DOES NOT CONTAIN ALL OF THE INFORMATION THAT YOU SHOULD CONSIDER BEFORE INVESTING IN OUR COMMON STOCK. YOU SHOULD READ THE ENTIRE PROSPECTUS CAREFULLY, ESPECIALLY THE DISCUSSION REGARDING THE RISKS OF INVESTING IN THE COMMON STOCK OF CALYPTE BIOMEDICAL CORPORATION UNDER THE SECTION ENTITLED "RISK FACTORS," BEFORE INVESTING IN CALYPTE BIOMEDICAL CORPORATION'S COMMON STOCK. REFERENCES IN THIS PROSPECTUS TO "WE," "US" AND "OUR" REFER TO CALYPTE BIOMEDICAL CORPORATION, A DELAWARE CORPORATION.
ABOUT CALYPTE BIOMEDICAL CORPORATION We develop, manufacture, and distribute in vitro diagnostic tests, primarily for the diagnosis of Human Immunodeficiency Virus ("HIV") infection. Historically, we have manufactured and marketed urine-based HIV-1 diagnostic screening tests and urine and serum-based Western Blot supplemental tests for use in laboratories, which we refer to as our "Legacy Business." Since we began marketing our urine diagnostic testing products following their approval by the FDA and through the first quarter of 2005, our revenues have been almost exclusively generated from sales of these products. The Legacy Business tests are manufactured in formats that make them most suitable for high-volume laboratory settings. Over the last two years, however, we have been broadening our historical focus to include other HIV tests, such as a blood-based incidence test and various rapid tests using other specimens. In the last quarter of 2004, we introduced our HIV-1 BED incidence EIA test (the "BED Incidence Test") that detects HIV-1 infections that have occurred within approximately the prior 6 months and that can be used by public health agencies to identify those regions and the populations within those regions where HIV transmission is occurring most recently. We are currently focusing on the development and commercialization of our new test products for the rapid detection of antibodies to HIV-1 and HIV Type 2, a second type of HIV ("HIV-2"), in blood, oral fluid and urine samples using a lateral flow dipstick design (the "HIV-1/2 Rapid Tests") and the commercialization of the BED Incidence Test on a worldwide basis. Rapid tests provide test results in less than 20 minutes and are particularly suitable for point-of-care testing, especially in lesser developed countries which lack the medical infrastructure to support laboratory based testing. We have completed field trials of our HIV-1/2 Rapid Tests that have validated our prototype products. We have recently completed clinical trials in Uganda and China and are currently engaged in clinical trials in other countries in pursuit of regulatory approvals for these tests. In an effort to reduce our cash burn rate and prolong our resources, in April 2005 we announced our plans to restructure our business (the "Plan") to consolidate our domestic operations and focus our capital resources on the global commercialization of the HIV-1/2 Rapid Tests and the BED Incidence Test. As part of the Plan, we are discontinuing the production of our Legacy Business products currently manufactured at our facility in Rockville, Maryland. Pursuant to the Plan, we will pursue various options ranging from selling the Legacy Business to discontinuing manufacturing operations at the Rockville facility pending a final determination of its disposition. In furtherance of the Plan, on April 18, 2005, we entered into a non-binding letter of intent to sell the Legacy Business to Maxim Biomedical, Inc. ("Maxim"). Effective May 1, 2005, we entered into a manufacturing services and management agreement (the "Agreement") with Maxim pursuant to which Maxim will manufacture, ship and perform quality control procedures for us in connection with the Legacy Business. Pursuant to the Agreement, Maxim has the right, but not the obligation, to purchase the assets of the Legacy Business on terms to be negotiated between the parties. We will remain liable for our Rockville facility and equipment lease obligations, however, we expect to lower our operating expenses through this arrangement. Over the next couple of months, we expect to complete either the sale of the Legacy Business to Maxim or the closure of the Rockville facility and termination of Legacy Business operations as well as the transition of our corporate headquarters to the Portland, Oregon area. We will incur severance costs for certain personnel terminated at Rockville and certain administrative personnel not transitioning to Oregon. Our restructuring activities are expected to result in severance-related charges of approximately $500,000. We also expect to incur approximately $1 million in expenses from the write-down of inventory. We may also be liable for lease costs for the California offices through July 2007 in the event we are unable to sublease that facility. Upon successful completion of a sale of the Legacy Business, we believe that we will have significantly reduced our monthly operating burn rate as compared with historical levels. If we are unable to complete such a transaction, we may incur costs to decommission the Rockville facilities; on-going facility lease costs, until and unless sub-lease opportunities are available and on-going lease or lease termination costs associated with leased equipment. We cannot currently estimate those costs, but they will increase our cash burn rate in comparison with the sale alternative. Under either scenario, the revenue stream from our Legacy Business products will have been eliminated and we will rely on revenues from the sale of our BED Incidence Test and, following regulatory approvals, from the sale of our HIV 1-2 Rapid Tests internationally. We believe that the geographic consolidation of our domestic operations and the termination of our Legacy Business resulting from this restructuring will improve our operational efficiency, decrease our cash burn and permit us to concentrate on expediting the procedures necessary to commercialize the HIV1-2 Rapid Tests and thereby begin the process of building the revenue stream necessary to support our operations and achieve our financial objective of sustained profitable operations and increased stockholder value.
THE OFFERING Total shares of common stock outstanding 171,243,303 as of May 16, 2005 Common stock offered for resale to the public 39,588,810 shares, of which 25,523,006 have been issued to selling security holders and are included in our outstanding shares and 14,065,804 shares which may be issuable upon exercise of outstanding warrants, conversion of convertible debentures or pursuant to consulting contracts. All of the shares offered by this Prospectus are being sold by the selling security holders Risk factors The shares involve a high degree of risk. Investors should carefully consider the information set forth under "RISK FACTORS" beginning on page 5. Use of proceeds We will not receive any proceeds from the sale of our common stock offered through this Prospectus by the selling security holders. All proceeds from the sale of our common stock sold under this Prospectus will go to the selling security holders. We will, however, receive an aggregate of up to $6,889,514 if the selling security holders exercise all of their warrants to purchase common stock. We would expect to use any such proceeds for general corporate purposes. Determination of offering price This Prospectus may be used from time to time by the selling security holders who offer our common stock in transactions (which may include block transactions) at prevailing market prices at the time of sale, at prices related to the prevailing market prices, or at other negotiated prices. The selling security holders will act independently in determining the offering price of each sale. Trading symbol for our common stock HIV
RISK FACTORS YOU SHOULD CAREFULLY CONSIDER THE RISKS DESCRIBED BELOW BEFORE DECIDING TO INVEST IN OUR COMMON STOCK. AN INVESTMENT IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. THE RISKS AND UNCERTAINTIES DESCRIBED BELOW ARE NOT THE ONLY ONES WE FACE. ADDITIONAL RISKS AND UNCERTAINTIES NOT PRESENTLY KNOWN TO US OR THAT WE CURRENTLY DEEM IMMATERIAL MAY ALSO IMPAIR OUR BUSINESS, FINANCIAL CONDITION AND RESULTS OF OPERATIONS. IF ANY OF THE FOLLOWING RISKS ACTUALLY OCCUR, OUR BUSINESS, FINANCIAL CONDITION AND RESULTS OF OPERATIONS COULD BE HARMED. IN THAT CASE, THE TRADING PRICE OF OUR COMMON STOCK COULD DECLINE, AND YOU COULD LOSE ALL OR PART OF YOUR INVESTMENT. IN ASSESSING THESE RISKS, YOU SHOULD ALSO REFER TO THE OTHER INFORMATION INCLUDED OR INCORPORATED BY REFERENCE IN THIS PROSPECTUS, INCLUDING OUR FINANCIAL STATEMENTS AND THE NOTES THERETO. WE DISCLAIM ANY OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENTS CONTAINED HEREIN AFTER THE DATE OF THIS PROSPECTUS.
Gruß
C.O
Das ist auch aus dem Filing (Aktuell)
PROSPECTUS SUMMARY THE FOLLOWING SUMMARY HIGHLIGHTS SELECTED INFORMATION CONTAINED ELSEWHERE IN THIS PROSPECTUS OR INCORPORATED BY REFERENCE IN THIS PROSPECTUS. THIS SUMMARY DOES NOT CONTAIN ALL OF THE INFORMATION THAT YOU SHOULD CONSIDER BEFORE INVESTING IN OUR COMMON STOCK. YOU SHOULD READ THE ENTIRE PROSPECTUS CAREFULLY, ESPECIALLY THE DISCUSSION REGARDING THE RISKS OF INVESTING IN THE COMMON STOCK OF CALYPTE BIOMEDICAL CORPORATION UNDER THE SECTION ENTITLED "RISK FACTORS," BEFORE INVESTING IN CALYPTE BIOMEDICAL CORPORATION'S COMMON STOCK. REFERENCES IN THIS PROSPECTUS TO "WE," "US" AND "OUR" REFER TO CALYPTE BIOMEDICAL CORPORATION, A DELAWARE CORPORATION.
ABOUT CALYPTE BIOMEDICAL CORPORATION We develop, manufacture, and distribute in vitro diagnostic tests, primarily for the diagnosis of Human Immunodeficiency Virus ("HIV") infection. Historically, we have manufactured and marketed urine-based HIV-1 diagnostic screening tests and urine and serum-based Western Blot supplemental tests for use in laboratories, which we refer to as our "Legacy Business." Since we began marketing our urine diagnostic testing products following their approval by the FDA and through the first quarter of 2005, our revenues have been almost exclusively generated from sales of these products. The Legacy Business tests are manufactured in formats that make them most suitable for high-volume laboratory settings. Over the last two years, however, we have been broadening our historical focus to include other HIV tests, such as a blood-based incidence test and various rapid tests using other specimens. In the last quarter of 2004, we introduced our HIV-1 BED incidence EIA test (the "BED Incidence Test") that detects HIV-1 infections that have occurred within approximately the prior 6 months and that can be used by public health agencies to identify those regions and the populations within those regions where HIV transmission is occurring most recently. We are currently focusing on the development and commercialization of our new test products for the rapid detection of antibodies to HIV-1 and HIV Type 2, a second type of HIV ("HIV-2"), in blood, oral fluid and urine samples using a lateral flow dipstick design (the "HIV-1/2 Rapid Tests") and the commercialization of the BED Incidence Test on a worldwide basis. Rapid tests provide test results in less than 20 minutes and are particularly suitable for point-of-care testing, especially in lesser developed countries which lack the medical infrastructure to support laboratory based testing. We have completed field trials of our HIV-1/2 Rapid Tests that have validated our prototype products. We have recently completed clinical trials in Uganda and China and are currently engaged in clinical trials in other countries in pursuit of regulatory approvals for these tests. In an effort to reduce our cash burn rate and prolong our resources, in April 2005 we announced our plans to restructure our business (the "Plan") to consolidate our domestic operations and focus our capital resources on the global commercialization of the HIV-1/2 Rapid Tests and the BED Incidence Test. As part of the Plan, we are discontinuing the production of our Legacy Business products currently manufactured at our facility in Rockville, Maryland. Pursuant to the Plan, we will pursue various options ranging from selling the Legacy Business to discontinuing manufacturing operations at the Rockville facility pending a final determination of its disposition. In furtherance of the Plan, on April 18, 2005, we entered into a non-binding letter of intent to sell the Legacy Business to Maxim Biomedical, Inc. ("Maxim"). Effective May 1, 2005, we entered into a manufacturing services and management agreement (the "Agreement") with Maxim pursuant to which Maxim will manufacture, ship and perform quality control procedures for us in connection with the Legacy Business. Pursuant to the Agreement, Maxim has the right, but not the obligation, to purchase the assets of the Legacy Business on terms to be negotiated between the parties. We will remain liable for our Rockville facility and equipment lease obligations, however, we expect to lower our operating expenses through this arrangement. Over the next couple of months, we expect to complete either the sale of the Legacy Business to Maxim or the closure of the Rockville facility and termination of Legacy Business operations as well as the transition of our corporate headquarters to the Portland, Oregon area. We will incur severance costs for certain personnel terminated at Rockville and certain administrative personnel not transitioning to Oregon. Our restructuring activities are expected to result in severance-related charges of approximately $500,000. We also expect to incur approximately $1 million in expenses from the write-down of inventory. We may also be liable for lease costs for the California offices through July 2007 in the event we are unable to sublease that facility. Upon successful completion of a sale of the Legacy Business, we believe that we will have significantly reduced our monthly operating burn rate as compared with historical levels. If we are unable to complete such a transaction, we may incur costs to decommission the Rockville facilities; on-going facility lease costs, until and unless sub-lease opportunities are available and on-going lease or lease termination costs associated with leased equipment. We cannot currently estimate those costs, but they will increase our cash burn rate in comparison with the sale alternative. Under either scenario, the revenue stream from our Legacy Business products will have been eliminated and we will rely on revenues from the sale of our BED Incidence Test and, following regulatory approvals, from the sale of our HIV 1-2 Rapid Tests internationally. We believe that the geographic consolidation of our domestic operations and the termination of our Legacy Business resulting from this restructuring will improve our operational efficiency, decrease our cash burn and permit us to concentrate on expediting the procedures necessary to commercialize the HIV1-2 Rapid Tests and thereby begin the process of building the revenue stream necessary to support our operations and achieve our financial objective of sustained profitable operations and increased stockholder value.
THE OFFERING Total shares of common stock outstanding 171,243,303 as of May 16, 2005 Common stock offered for resale to the public 39,588,810 shares, of which 25,523,006 have been issued to selling security holders and are included in our outstanding shares and 14,065,804 shares which may be issuable upon exercise of outstanding warrants, conversion of convertible debentures or pursuant to consulting contracts. All of the shares offered by this Prospectus are being sold by the selling security holders Risk factors The shares involve a high degree of risk. Investors should carefully consider the information set forth under "RISK FACTORS" beginning on page 5. Use of proceeds We will not receive any proceeds from the sale of our common stock offered through this Prospectus by the selling security holders. All proceeds from the sale of our common stock sold under this Prospectus will go to the selling security holders. We will, however, receive an aggregate of up to $6,889,514 if the selling security holders exercise all of their warrants to purchase common stock. We would expect to use any such proceeds for general corporate purposes. Determination of offering price This Prospectus may be used from time to time by the selling security holders who offer our common stock in transactions (which may include block transactions) at prevailing market prices at the time of sale, at prices related to the prevailing market prices, or at other negotiated prices. The selling security holders will act independently in determining the offering price of each sale. Trading symbol for our common stock HIV
RISK FACTORS YOU SHOULD CAREFULLY CONSIDER THE RISKS DESCRIBED BELOW BEFORE DECIDING TO INVEST IN OUR COMMON STOCK. AN INVESTMENT IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. THE RISKS AND UNCERTAINTIES DESCRIBED BELOW ARE NOT THE ONLY ONES WE FACE. ADDITIONAL RISKS AND UNCERTAINTIES NOT PRESENTLY KNOWN TO US OR THAT WE CURRENTLY DEEM IMMATERIAL MAY ALSO IMPAIR OUR BUSINESS, FINANCIAL CONDITION AND RESULTS OF OPERATIONS. IF ANY OF THE FOLLOWING RISKS ACTUALLY OCCUR, OUR BUSINESS, FINANCIAL CONDITION AND RESULTS OF OPERATIONS COULD BE HARMED. IN THAT CASE, THE TRADING PRICE OF OUR COMMON STOCK COULD DECLINE, AND YOU COULD LOSE ALL OR PART OF YOUR INVESTMENT. IN ASSESSING THESE RISKS, YOU SHOULD ALSO REFER TO THE OTHER INFORMATION INCLUDED OR INCORPORATED BY REFERENCE IN THIS PROSPECTUS, INCLUDING OUR FINANCIAL STATEMENTS AND THE NOTES THERETO. WE DISCLAIM ANY OBLIGATION TO UPDATE ANY FORWARD-LOOKING STATEMENTS CONTAINED HEREIN AFTER THE DATE OF THIS PROSPECTUS.
Gruß
C.O
19.05.05 12:14
#403
Brokersince1994
Wir sind voll dabei, daß heißt schwer dabei
und werden sehr bald das ernten was wir verdient haben...
Ich werde dich mit dem überraschen was wir uns gegenseitig versprochen hatten...
Gruß
C.O
und werden sehr bald das ernten was wir verdient haben...
Ich werde dich mit dem überraschen was wir uns gegenseitig versprochen hatten...
Gruß
C.O
19.05.05 13:30
#404
Brokersince1994
Joelu willst du vergleichen ??
Yahoo Board
by surfstockguy
Heres a home kit
http_//www.craigmedical.com/HIV_home.htm
it sells for $59.00
lets assume from manufacturers price anywhere from 260 - 400 % markup. This is common in specialty, niche markets. If you add Hepatitis its over $120.
So lets assume for HIV the manufacturer is getting $15 worst case.
Thats for America OTC
by surfstockguy
Heres a home kit
http_//www.craigmedical.com/HIV_home.htm
it sells for $59.00
lets assume from manufacturers price anywhere from 260 - 400 % markup. This is common in specialty, niche markets. If you add Hepatitis its over $120.
So lets assume for HIV the manufacturer is getting $15 worst case.
Thats for America OTC
19.05.05 13:34
#405
Brokersince1994
Another Blood Test Cost Link - Elisa vs
Kallenborn Jc, et al., Emergency department management of occupational exposures: cost analysis of rapid HIV test. Infect Control Hosp Epidemiol, 2001. 22(5): p. 289 93.
OBJECTIVE: To compare costs for evaluation and treatment of a healthcare worker (HCW) experiencing an occupational exposure, using a rapid human immunodeficiency virus (HIV) test versus a standard enzyme linked immunosorbent assay (ELISA) HIV test. DESIGN: Retrospective chart review of all HCWs presenting to the emergency department (ED) for care of an occupational exposure over a 13 month period. SETTING: A 404 bed university based level 1 trauma center with an annual ED census of approximately 35,000. PARTICIPANTS: All HCWs experiencing an occupational exposure treated in the ED using a rapid HIV protocol were included in the analysis. METHODS: A calculation of selected costs of the initial evaluation and treatment of patients whose evaluation included a rapid HIV test on the source patient were performed. A similar calculation was then made for these patients, had the standard ELISA test been used. Evaluated costs included laboratory tests, postexposure prophylactic medications, and estimated lost work time. Other costs were constant and were not included in the evaluation. RESULTS: Total evaluated cost using the rapid HIV test as part of the evaluation and treatment protocol was $465.80 for 17 patients. Had the ELISA test been used instead of the rapid test, the total evaluated cost for the 17 patients would have been $5,965.81. CONCLUSIONS: When used as part of the evaluation and treatment of the HCW with an occupational exposure, the rapid HIV test results in substantial cost savings over the ELISA test.
And cost directly from WHO for those
by: surfstockguy
that dont have it:
http_//www.who.int/3by5/en/HIVtestkit.pdf#search='hiv%20test%20cost'
In it you will see:
Test Ave Cost Bulk Cost
ELISA 1.00 to 2.00 0.50
Simple/Rapid 2.00 to 8.00 1.00
Confirmatory 20.00 to 30.00 11.00
Use this info, with the previous cost study info. And you will see
1) the savings of using rapid over ELISA.
2)What our "competatively priced" Rapid tests will sell for
Kallenborn Jc, et al., Emergency department management of occupational exposures: cost analysis of rapid HIV test. Infect Control Hosp Epidemiol, 2001. 22(5): p. 289 93.
OBJECTIVE: To compare costs for evaluation and treatment of a healthcare worker (HCW) experiencing an occupational exposure, using a rapid human immunodeficiency virus (HIV) test versus a standard enzyme linked immunosorbent assay (ELISA) HIV test. DESIGN: Retrospective chart review of all HCWs presenting to the emergency department (ED) for care of an occupational exposure over a 13 month period. SETTING: A 404 bed university based level 1 trauma center with an annual ED census of approximately 35,000. PARTICIPANTS: All HCWs experiencing an occupational exposure treated in the ED using a rapid HIV protocol were included in the analysis. METHODS: A calculation of selected costs of the initial evaluation and treatment of patients whose evaluation included a rapid HIV test on the source patient were performed. A similar calculation was then made for these patients, had the standard ELISA test been used. Evaluated costs included laboratory tests, postexposure prophylactic medications, and estimated lost work time. Other costs were constant and were not included in the evaluation. RESULTS: Total evaluated cost using the rapid HIV test as part of the evaluation and treatment protocol was $465.80 for 17 patients. Had the ELISA test been used instead of the rapid test, the total evaluated cost for the 17 patients would have been $5,965.81. CONCLUSIONS: When used as part of the evaluation and treatment of the HCW with an occupational exposure, the rapid HIV test results in substantial cost savings over the ELISA test.
And cost directly from WHO for those
by: surfstockguy
that dont have it:
http_//www.who.int/3by5/en/HIVtestkit.pdf#search='hiv%20test%20cost'
In it you will see:
Test Ave Cost Bulk Cost
ELISA 1.00 to 2.00 0.50
Simple/Rapid 2.00 to 8.00 1.00
Confirmatory 20.00 to 30.00 11.00
Use this info, with the previous cost study info. And you will see
1) the savings of using rapid over ELISA.
2)What our "competatively priced" Rapid tests will sell for
19.05.05 13:42
#406
Brokersince1994
habt Ihr das gesehen ???
Ich finde das Interressant..
http://www.who.int/diagnostics_laboratory/...en/hiv_assays_rep_13.pdf
Gruß
C.O
Ich finde das Interressant..
http://www.who.int/diagnostics_laboratory/...en/hiv_assays_rep_13.pdf
Gruß
C.O
19.05.05 14:02
#407
Brokersince1994
es ist das alte aber so könnten auch
die Rapid Daten aussehen...
die Rapid Daten aussehen...
19.05.05 14:56
#408
Joelu_2ID
Löschung
Moderation
Zeitpunkt: 19.05.05 20:06
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer
Kommentar: Regelverstoß
Zeitpunkt: 19.05.05 20:06
Aktionen: Löschung des Beitrages, Nutzer-Sperre für immer
Kommentar: Regelverstoß
19.05.05 17:09
#410
Kade_I
Ach joelu, was soll man dazu noch sagen ...
irgendwie kann ich ein Ahndung solcher Drohungen und Beleidigungen schon verstehen ...
"ich biete dir ja an: als geistig verwirrter bekommst du in engelskirchen eine spezialbehandlung in form von elektrotherapie...
vielleicht fällt es dir hinterher nicht mehr so schwer, die wahrheit zu akzeptieren..."
Aber wenn Du meinst das ist ok-- dann Prost Mahlzeit !
"ich biete dir ja an: als geistig verwirrter bekommst du in engelskirchen eine spezialbehandlung in form von elektrotherapie...
vielleicht fällt es dir hinterher nicht mehr so schwer, die wahrheit zu akzeptieren..."
Aber wenn Du meinst das ist ok-- dann Prost Mahlzeit !
20.05.05 09:05
#411
Brokersince1994
Verschiedene Beiträge....
WHO's analyis and test results
Here are links to WHO's analysis of HIV tests. Notice there are only three Urine tests in report, and there are no rapid urine tests (pre-ANI), All rapid tests are blood based. so even the cheapest rapid blood test (at .60 in '95) still requires blood to be drawn thus adding expense. Even if Calypte sold thier test kits at $3.00 it would still be cheaper on a per test basis.
whole blood
http_//www.who.int/entity/diagnostics_laboratory/...en/hiv_assays_rep_12.pdf
urine & saliva
http_//www.who.int/entity/diagnostics_laboratory/...en/hiv_assays_rep_13.pdf
rapid (blood)
http_//www.who.int/entity/diagnostics_laboratory/...en/hiv_assays_rep_14.pdf
you do the Math..
by: readssthe10qs
present cost to produce urine lab tests, approximately $ 2 . (This doesn't include about $10 million in overhead S,G,and A expenses.)
New costs of rapid test to Abbott, Bio-rad, Ani etc. = $ .25 per test.
Cost to produce = $ 2.25 per test.
A. If Marr gets 50% of Profit on each Chinese test and cost of production remains constant at what porice must HIV sell their tests just to make a $ .50 gross profit per test.
B. If Marr gets 50% of profit and tests in China are sold at $ 1.50 as per Tony Cataldo's speeches (only 50% above market competitors)
at what price must HIV manufacture the tests in China to net a $.50 profit per test?
.....
A. $ 3.25, or 3.25 times what other rapid tests are being sold for. Then there is that pesky 10 million in overhead to cover, but thats breaks even at 20 million tests or 65 million in total sales at $ 3.25 per test.
B. $ .50 per test production cost about a than a fourth of the present cost of the lab urine test, before the additional $ .25 pet test is added for new patent holders. So that means a $ .25 per test production cost on a comparison basis with the $ 2.00 present cost of urione lab test.
Yep all they have to do is lower the production cost from $ 2.00 per test to $ .25 per test and sell 20 million tests at $ 1.50 per test (or 1.5 times what all their competitors are selling for) to break even.
Wait a sec I forgot to put in a cost factor of the distributors selling the test. Lets be real kind and call that cost $ .10 per test .So the cost of production will need to be $ .15 per test for the $ 1.50 test to make a $ .50 gross profit per test.
You don't even want to try this math if Calypte has to charge the $ 1 price all their competitors are charging.
No wonder Dr. George didn't want to address the cost per test price.
I do appreciate Dr.George's honest answer about the possibility of FDA approving any OTC use of HIV's rapid tests. In spite of Tony Cataldo's mention of rapid tests being sold out of vending machines and the local hysters pumping it, there is no effort being made in this area.
If any of HIV's rapid tests are sold in US, wouldn't they have to be FDA approved and therefore manufactured in US to get that FDA approval?
I hope Lake Oswego is not nervous about explosive chemicals also.
Maybe they could put a sign out front of the new home offices that says:
"Urine, you could bathe in it, you could even drink it.."
Nah, maybe not.
Here is a picture of Roy Hinkley when HIV makes a SEC filing.
http://www.msnusers.com/cmkx2/shoebox.msnw?action=ShowPhoto&PhotoID=48
....duh.....POPULATION OF CHINA IS 1.4 BILLION
Less than 1% of the chinese population is being tested for HIV right now.
The Chinese government wants to implement testing for everyone. First with sex trade workers - 30 Million - (basically the entire population of Canada) being tested 1x per quarter = 120M HIV tests
Add mandatory testing of convicts - 50Million
Next, the Chinese government wants to test all women of childbearing years - 200-300 Million
Abbott is "donating" 1 Million free rapid BLOOD tests WORLDWIDE... That wouldn't even test 0.5% of the PG women in China.
Name a company that makes enough $1 rapid blood HIV tests to test all the PG women in China, who's over there right now selling their product! Go ahead & name them or shut up!
And don't forget the Chinese culture - many are illiterate. Go to a bank on Mainline china & people still use Chop-Block banking (basically an ivory block that is used as a signature stamp) b/c people can't read/write. The government will never be able to test it's population effectively if blood has to be drawn.
Take a look at the Chinese communist system. How do they maintain a 1 child policy? Illiterate villagers are monitored by district health people. In some villages, only the district health nurse is literate.
People don't like dealing with blood.
Gruß
C.O
WHO's analyis and test results
Here are links to WHO's analysis of HIV tests. Notice there are only three Urine tests in report, and there are no rapid urine tests (pre-ANI), All rapid tests are blood based. so even the cheapest rapid blood test (at .60 in '95) still requires blood to be drawn thus adding expense. Even if Calypte sold thier test kits at $3.00 it would still be cheaper on a per test basis.
whole blood
http_//www.who.int/entity/diagnostics_laboratory/...en/hiv_assays_rep_12.pdf
urine & saliva
http_//www.who.int/entity/diagnostics_laboratory/...en/hiv_assays_rep_13.pdf
rapid (blood)
http_//www.who.int/entity/diagnostics_laboratory/...en/hiv_assays_rep_14.pdf
you do the Math..
by: readssthe10qs
present cost to produce urine lab tests, approximately $ 2 . (This doesn't include about $10 million in overhead S,G,and A expenses.)
New costs of rapid test to Abbott, Bio-rad, Ani etc. = $ .25 per test.
Cost to produce = $ 2.25 per test.
A. If Marr gets 50% of Profit on each Chinese test and cost of production remains constant at what porice must HIV sell their tests just to make a $ .50 gross profit per test.
B. If Marr gets 50% of profit and tests in China are sold at $ 1.50 as per Tony Cataldo's speeches (only 50% above market competitors)
at what price must HIV manufacture the tests in China to net a $.50 profit per test?
.....
A. $ 3.25, or 3.25 times what other rapid tests are being sold for. Then there is that pesky 10 million in overhead to cover, but thats breaks even at 20 million tests or 65 million in total sales at $ 3.25 per test.
B. $ .50 per test production cost about a than a fourth of the present cost of the lab urine test, before the additional $ .25 pet test is added for new patent holders. So that means a $ .25 per test production cost on a comparison basis with the $ 2.00 present cost of urione lab test.
Yep all they have to do is lower the production cost from $ 2.00 per test to $ .25 per test and sell 20 million tests at $ 1.50 per test (or 1.5 times what all their competitors are selling for) to break even.
Wait a sec I forgot to put in a cost factor of the distributors selling the test. Lets be real kind and call that cost $ .10 per test .So the cost of production will need to be $ .15 per test for the $ 1.50 test to make a $ .50 gross profit per test.
You don't even want to try this math if Calypte has to charge the $ 1 price all their competitors are charging.
No wonder Dr. George didn't want to address the cost per test price.
I do appreciate Dr.George's honest answer about the possibility of FDA approving any OTC use of HIV's rapid tests. In spite of Tony Cataldo's mention of rapid tests being sold out of vending machines and the local hysters pumping it, there is no effort being made in this area.
If any of HIV's rapid tests are sold in US, wouldn't they have to be FDA approved and therefore manufactured in US to get that FDA approval?
I hope Lake Oswego is not nervous about explosive chemicals also.
Maybe they could put a sign out front of the new home offices that says:
"Urine, you could bathe in it, you could even drink it.."
Nah, maybe not.
Here is a picture of Roy Hinkley when HIV makes a SEC filing.
http://www.msnusers.com/cmkx2/shoebox.msnw?action=ShowPhoto&PhotoID=48
....duh.....POPULATION OF CHINA IS 1.4 BILLION
Less than 1% of the chinese population is being tested for HIV right now.
The Chinese government wants to implement testing for everyone. First with sex trade workers - 30 Million - (basically the entire population of Canada) being tested 1x per quarter = 120M HIV tests
Add mandatory testing of convicts - 50Million
Next, the Chinese government wants to test all women of childbearing years - 200-300 Million
Abbott is "donating" 1 Million free rapid BLOOD tests WORLDWIDE... That wouldn't even test 0.5% of the PG women in China.
Name a company that makes enough $1 rapid blood HIV tests to test all the PG women in China, who's over there right now selling their product! Go ahead & name them or shut up!
And don't forget the Chinese culture - many are illiterate. Go to a bank on Mainline china & people still use Chop-Block banking (basically an ivory block that is used as a signature stamp) b/c people can't read/write. The government will never be able to test it's population effectively if blood has to be drawn.
Take a look at the Chinese communist system. How do they maintain a 1 child policy? Illiterate villagers are monitored by district health people. In some villages, only the district health nurse is literate.
People don't like dealing with blood.
Gruß
C.O
20.05.05 13:32
#412
Franz_W
Löschung
Moderation
Zeitpunkt: 24.05.05 14:13
Aktionen: Löschung des Beitrages, Nutzer-Sperre für 2 Stunden
Kommentar: Regelverstoß
Zeitpunkt: 24.05.05 14:13
Aktionen: Löschung des Beitrages, Nutzer-Sperre für 2 Stunden
Kommentar: Regelverstoß
20.05.05 14:33
#413
Brokersince1994
@Franz_W
Ihr nervt die anderen hier mit eurem Gezanke ungemein. Allerdings muß ich auch ganz klar sagen, das es in anderen Boards schlimmer zugeht und ich darum über die Löschung der vielen Postings schon überrascht und amüsiert bin. Als ansonsten stiller Leser muß ich mich doch mal zu Wort melden.
Wenn ich mir allerdings den 4-Jahres-Chart ansehe, frage ich mich allen Ernstes, ob die hier Investierten noch ganz dicht sind. Klar, Joelu ist super penetrant mit seinem Auftritt, hat aber im Grunde doch recht.
Kade, Du musst wirklich das Gehirn eines Rattenfikkers haben, wenn du wirklich noch die Story glaubst. Sorry dafür, aber man muß wirklich nicht mehr alle Tassen im Schrank haben, um deinen Senf ständig abzugeben.
@Franz_W
Hast du uns etwas besseres anzubieten??
Wir sind alle offen für gute Vorschläge, hast du event. Einige Vorschläge (Werte) wovon wir Unterrichtet werden sollten...
Ich kann nur sagen, das wirst auch du bestätigen , das wir in den letzten 5 Jahren keine festen Werte mehr hatten, einschließlich Standartwerte.....
Wie gesagt wir sind ganz Ohr....
Gruß
C.O
Wenn ich mir allerdings den 4-Jahres-Chart ansehe, frage ich mich allen Ernstes, ob die hier Investierten noch ganz dicht sind. Klar, Joelu ist super penetrant mit seinem Auftritt, hat aber im Grunde doch recht.
Kade, Du musst wirklich das Gehirn eines Rattenfikkers haben, wenn du wirklich noch die Story glaubst. Sorry dafür, aber man muß wirklich nicht mehr alle Tassen im Schrank haben, um deinen Senf ständig abzugeben.
@Franz_W
Hast du uns etwas besseres anzubieten??
Wir sind alle offen für gute Vorschläge, hast du event. Einige Vorschläge (Werte) wovon wir Unterrichtet werden sollten...
Ich kann nur sagen, das wirst auch du bestätigen , das wir in den letzten 5 Jahren keine festen Werte mehr hatten, einschließlich Standartwerte.....
Wie gesagt wir sind ganz Ohr....
Gruß
C.O
21.05.05 03:12
#414
Franz_W
Hallo C.O.
Wenn Du mich fragst, also ich habe mir Mitte/Ende April Lufthansa-Aktien geholt für ca. 10,30€. Die WM 2006 steht bevor, da wird das Teil im nächsten Jahr stark nach oben ziehen. Es finden jede Menge Transporte der Leute statt und man wird damit rechnen, das der Umsatz stark steigt.
Sofern Dir auch mal 30 - 40 - 50% reichen. Ich bin halt mit einer 5-stelligen Summe drin, da machen 30% auch schon was aus. Natürlich nicht so spektakulär wie Calypte, aber was bringt Dir ein stetiger Kursverfall und die geringe Chance, das es klappt?
Das ist mein Rat an Dich. Er ist natürlich gediegen, aber Du kannst im Urlaub den Wert auch einmal aus den Augen lassen.
Also das mit Calypte wird nichts. Es würde mich wundern, wenn die noch die Kurve bekommen. Habe eigentlich noch nie einen Wert mit dem 4-Jahreschart gesehen, der dann noch die Kurve bekommen hat. Ich vermute auch, das hier vor einiger Zeit schon ein Reverse Splitt stattgefunden hat, der aber wohl nicht den gewünschten Erfolg zeigte.
Schönes Wochenende.
Sofern Dir auch mal 30 - 40 - 50% reichen. Ich bin halt mit einer 5-stelligen Summe drin, da machen 30% auch schon was aus. Natürlich nicht so spektakulär wie Calypte, aber was bringt Dir ein stetiger Kursverfall und die geringe Chance, das es klappt?
Das ist mein Rat an Dich. Er ist natürlich gediegen, aber Du kannst im Urlaub den Wert auch einmal aus den Augen lassen.
Also das mit Calypte wird nichts. Es würde mich wundern, wenn die noch die Kurve bekommen. Habe eigentlich noch nie einen Wert mit dem 4-Jahreschart gesehen, der dann noch die Kurve bekommen hat. Ich vermute auch, das hier vor einiger Zeit schon ein Reverse Splitt stattgefunden hat, der aber wohl nicht den gewünschten Erfolg zeigte.
Schönes Wochenende.
21.05.05 12:50
#415
Brokersince1994
Um Ein Unternehmen Richtig kennenzulernen muß man
sich damit auseinander setzen. Richtig?
Calypte ist auf dem Besten Wege nach oben zwar haben wir bis jetzt nichts gespürt aber das kommt noch.
Du wirst Ende dieses Jahres die Lohrbeeren ernten nicht wahr?
Dann kannst du ja auch hier rein schauen O.K
Gruß
C.O
sich damit auseinander setzen. Richtig?
Calypte ist auf dem Besten Wege nach oben zwar haben wir bis jetzt nichts gespürt aber das kommt noch.
Du wirst Ende dieses Jahres die Lohrbeeren ernten nicht wahr?
Dann kannst du ja auch hier rein schauen O.K
Gruß
C.O
24.05.05 13:55
#416
Kade_I
Stellungnahme:
Nachdem meine ID die letzten Tage gesperrt war, weil mich JOELU für jedes kleinste Unwort (Z.B. "Herr laß Hirn regnen") -teilweise aus Postings aus 2004!-bei Ariva angeschwärzt hat, und Ariva dieses auch noch mitgemacht hat, teile ich hiermit mit, dass ich diesen Kindergarten nicht mehr mit mache !
Macht euch einfach selbst die Arbeit und sucht Infos zu Artikel im Netz. Ich werde hier nur noch bedingt etwas einstellen (siehe Jobanzeigen von Calypte in China usw.). Es ist einfach zu kindisch hier, besonders was JOELU hier abzieht (für jedermann nachzuverfolgen). Dafür ist mir meine Zeit definitiv zu schade ...
Hierfür wurde ich gesperrt- man achte auch darauf, dass ich in diesen Postings niemals jemanden persönlich per Namen anspreche:
Kade_I 18.05.05 18:51
auf das gleiche habe ich Dir mindestens schon
5x geantwortet ! Laß Hirn regnen !
Weshab Grüße nach München?!
Kade_I 10.05.05 16:05 Nicht Namen sonder Ruf ...
Verlierer
Kade_I 13.05.05 12:19 Wer faselt hier andauernd vom Penthouse ?
Man nennt ihn Mizo, denn er ist Schizo ...
In welcher Welt lebst Du eigenlich ? Du schreibst und antwortest Dir mittlerweile schon selbst !
GET A LIFE !!!!
Kade_I 12.01.05 17:13 Selbstgespräche, Selbstbefriedigung, Selbstzweifel
Eine traurige Gestalt ...
Auch für einen namen- und kommetarlosen "Psycho" gabs einen Extra-Tag Sperre !
Wow, ich sage nur Respekt für diese tolle Leistung !
Aber Hauptsache Postings wie #412 bleiben hier im Board stehen ...
Grüße an Borker, Lucky, gindants ... und alle LONGS !
Kade_I
P.S.: Wer ist Franz_W von #412 ? Am Tag als joelu gesperrt wurde, entstand diese ID ! Bestimmt nur Zufall ! LOL
Macht euch einfach selbst die Arbeit und sucht Infos zu Artikel im Netz. Ich werde hier nur noch bedingt etwas einstellen (siehe Jobanzeigen von Calypte in China usw.). Es ist einfach zu kindisch hier, besonders was JOELU hier abzieht (für jedermann nachzuverfolgen). Dafür ist mir meine Zeit definitiv zu schade ...
Hierfür wurde ich gesperrt- man achte auch darauf, dass ich in diesen Postings niemals jemanden persönlich per Namen anspreche:
Kade_I 18.05.05 18:51
auf das gleiche habe ich Dir mindestens schon
5x geantwortet ! Laß Hirn regnen !
Weshab Grüße nach München?!
Kade_I 10.05.05 16:05 Nicht Namen sonder Ruf ...
Verlierer
Kade_I 13.05.05 12:19 Wer faselt hier andauernd vom Penthouse ?
Man nennt ihn Mizo, denn er ist Schizo ...
In welcher Welt lebst Du eigenlich ? Du schreibst und antwortest Dir mittlerweile schon selbst !
GET A LIFE !!!!
Kade_I 12.01.05 17:13 Selbstgespräche, Selbstbefriedigung, Selbstzweifel
Eine traurige Gestalt ...
Auch für einen namen- und kommetarlosen "Psycho" gabs einen Extra-Tag Sperre !
Wow, ich sage nur Respekt für diese tolle Leistung !
Aber Hauptsache Postings wie #412 bleiben hier im Board stehen ...
Grüße an Borker, Lucky, gindants ... und alle LONGS !
Kade_I
P.S.: Wer ist Franz_W von #412 ? Am Tag als joelu gesperrt wurde, entstand diese ID ! Bestimmt nur Zufall ! LOL
24.05.05 14:13
#417
Brokersince1994
Kade es ist wirklich wieder Mal wahr ,
was du berichtest ; )
Zürückziehen und genießen ist einfach viel bescheidener als das hier mit Kindern sage Ich Mal auch wenn Ich dafür gesperrt werden sollte *g*
Deswegen die passende Antwort von mir bezügl. Franz_W
Lustig, Lustig Tr....
Gruß
C.O
was du berichtest ; )
Zürückziehen und genießen ist einfach viel bescheidener als das hier mit Kindern sage Ich Mal auch wenn Ich dafür gesperrt werden sollte *g*
Deswegen die passende Antwort von mir bezügl. Franz_W
Lustig, Lustig Tr....
Gruß
C.O
24.05.05 14:27
#418
gindants
hey jungs!
einfach locker bleiben. war auch schon wegen joelu gesperrt als er mich ne art mit einem mitläufer des nationalsozialismus veglich...
naja easy!!
naja easy!!
24.05.05 14:37
#419
Brokersince1994
Grüße dich gindants ; )
Ich hoffe alles bestens bei dir ...
Gruß
C.O
Ich hoffe alles bestens bei dir ...
Gruß
C.O
28.05.05 22:48
#420
Brokersince1994
Directors and Officers
Shares
Beneficially % of 5% Stockholders, Directors and Officers (1) Owned Total (2)
------------------------------------------- ----- ---------
Marr Technologies BV (3) 59,062,225 32.12 %
Strawinskylaan 1431
1077XX, Amsterdam
The Netherlands
SF Capital Partners Ltd. (4) 18,050,000 9.99 %
3600 South Lake Drive
St. Francis, WI 53235
Roger I. Gale (5) 1,215,000 *
J. Richard George (6) 5,075,717 2.88 %
Richard D. Brounstein (7) 2,257,371 1.30 %
John J. DiPietro (8) 307,977 *
Paul E. Freiman (9) 309,901 *
Julius Krevans, M.D.(10) 308,468 *
Maxim A. Soulimov (11) 200,000 *
Richard R. Van Maanen (12) 2,053,589 1.19 %
All current directors and executive officers as a group (8 persons) 11,728,023 6.42 %
Damit wäre das Thema auch vom Tisch Endgültig insbesondere für unseren Joelü
Gruß
C.O
Beneficially % of 5% Stockholders, Directors and Officers (1) Owned Total (2)
------------------------------------------- ----- ---------
Marr Technologies BV (3) 59,062,225 32.12 %
Strawinskylaan 1431
1077XX, Amsterdam
The Netherlands
SF Capital Partners Ltd. (4) 18,050,000 9.99 %
3600 South Lake Drive
St. Francis, WI 53235
Roger I. Gale (5) 1,215,000 *
J. Richard George (6) 5,075,717 2.88 %
Richard D. Brounstein (7) 2,257,371 1.30 %
John J. DiPietro (8) 307,977 *
Paul E. Freiman (9) 309,901 *
Julius Krevans, M.D.(10) 308,468 *
Maxim A. Soulimov (11) 200,000 *
Richard R. Van Maanen (12) 2,053,589 1.19 %
All current directors and executive officers as a group (8 persons) 11,728,023 6.42 %
Damit wäre das Thema auch vom Tisch Endgültig insbesondere für unseren Joelü
Gruß
C.O
30.05.05 11:59
#421
Brokersince1994
Calypte über UK Site ??
http://www.framedshare.co.uk/Product.asp?shareid=9050
Gruß
C.O
http://www.framedshare.co.uk/Product.asp?shareid=9050
Gruß
C.O
30.05.05 12:11
#422
Brokersince1994
Habe noch was gefunden, ein Bericht über BED In.
http://bbriefings.com/pdf/1043/Calypte_tech.pdf
Gruß
C.O
http://bbriefings.com/pdf/1043/Calypte_tech.pdf
Gruß
C.O
30.05.05 16:40
#423
joelu
Charttechnik:
Support/Resistance
Type Value Conf.
resist. 0.42 2
resist. 0.40 2
resist. 0.33 12
resist. 0.30 6
resist. 0.28 6
resist. 0.27 11
resist. 0.26 6
resist. 0.25 4
resist. 0.24 4
resist. 0.23 11
supp 0.22 2
supp 0.21 2
supp 0.20 10
wann fallen die 0,20$?
Type Value Conf.
resist. 0.42 2
resist. 0.40 2
resist. 0.33 12
resist. 0.30 6
resist. 0.28 6
resist. 0.27 11
resist. 0.26 6
resist. 0.25 4
resist. 0.24 4
resist. 0.23 11
supp 0.22 2
supp 0.21 2
supp 0.20 10
wann fallen die 0,20$?